PRÄPARATIONEN, DIE VIRUS-ÄHNLICHE PARTIKEL ALS IMMUNPOTENTIATOREN ENTHALTEN UND DURCH DIE SCHLEIMHAUT VERABREICHT WERDEN

The present invention is related to the branch of medicine, particularly to the new formulations of vaccine antigens. The technical objective pursued with the present invention is, precisely, the development of formulations that are able to enhance the immune response to mucosally administered antig...

Full description

Saved in:
Bibliographic Details
Main Authors IGLESIAS PEREZ, ENRIQUE, GUILLEN NIETO, GERARDO ENRIQUE, PICHARDO DIAZ, DAGMARA, MUZIO GONZALEZ, VERENA LUCILA, AGUILAR, RUBIDO JULIO CESAR, PALENZUELA GARDON. DANIEL OCTAVIO, PENTON ARIAS, EDUARDO
Format Patent
LanguageGerman
Published 15.07.2006
Edition7
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention is related to the branch of medicine, particularly to the new formulations of vaccine antigens. The technical objective pursued with the present invention is, precisely, the development of formulations that are able to enhance the immune response to mucosally administered antigens, minimising the number of compounds in the formulation and generating strong mucosal and systemic responses through a synergic interaction between the antigens in the formulation. These formulations enable: a) to broaden the spectrum of the anti-hepatitis B immune response, containing as main compounds HBsAg and HBcAg, b) to enhance the response against HBsAg with a viral nucleocapsid c) to generate combined vaccines through the mucosal route with HBsAg as a central antigen. Stabilizers and preservatives can be introduced. The formulations of this invention can be applied in the pharmaceutical industry as human or veterinary vaccine formulations.
Bibliography:Application Number: AT19990957844T